Highly selective inhibition of inducible nitric oxide synthase in vitro by a tripeptide as a new arginine analog.
- Author:
Fei SUN
1
;
Sai-zhu WU
;
Xiao-tian ZHANG
;
Chang-qing LIU
Author Information
- Publication Type:Journal Article
- MeSH: Arginine; analogs & derivatives; pharmacology; Blotting, Western; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; cytology; drug effects; enzymology; Humans; Insulin; pharmacology; Lipopolysaccharides; pharmacology; Macrophages; drug effects; enzymology; metabolism; Nitric Oxide; metabolism; Nitric Oxide Synthase Type II; antagonists & inhibitors; metabolism; Oligopeptides; chemistry; pharmacology
- From: Journal of Southern Medical University 2006;26(10):1431-1433
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the inhibitory effect of a tripeptide, a new arginine analog, on nitric oxide (NO) production and inducible nitric oxide synthase (iNOS).
METHODSMacrophages challenged with lipopolysaccharide were cultured to test the inhibitory effect of the arginine analog of different concentrations on iNOS. Primarily cultured human umbilical vein endothelial cells (HUVECs) treated with insulin were used to test the effect of the analog on endothelial NOS (eNOS).
RESULTSThe new arginine analog significantly inhibited NO production in the macrophages in a dose-dependent manner, but had little effect on insulin-stimulated NO production in HUVECs. The new analog could significantly suppress iNOS activity, but had no significant inhibitory effect on constitutive NOS activity or eNOS activity. Western blot analysis showed that the new analog did not significantly affect the protein expression of iNOS.
CONCLUSIONThe new analog is a NOS inhibitor with high selectivity on iNOS.
